{"version":"1.0","provider_name":"Association Fran\u00e7aise Ataxie de Friedreich","provider_url":"https:\/\/www.afaf.asso.fr","author_name":"Caroline Gaboriau","author_url":"https:\/\/www.afaf.asso.fr\/author\/caroline_gaboriau\/","title":"Actualit\u00e9 Vatiquinone - Association Fran\u00e7aise Ataxie de Friedreich","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"S1eMLgy6Mb\"><a href=\"https:\/\/www.afaf.asso.fr\/2025\/08\/31\/actualite-vatiquinone\/\">Actualit\u00e9 Vatiquinone<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.afaf.asso.fr\/2025\/08\/31\/actualite-vatiquinone\/embed\/#?secret=S1eMLgy6Mb\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Actualit\u00e9 Vatiquinone\u00a0\u00bb &#8212; Association Fran\u00e7aise Ataxie de Friedreich\" data-secret=\"S1eMLgy6Mb\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.afaf.asso.fr\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","thumbnail_width":3552,"thumbnail_height":2362,"description":"La vatiquinone, d\u00e9velopp\u00e9e par PTC Therapeutics, \u00a0est une petite mol\u00e9cule, inhibiteur s\u00e9lectif de la 15-lipoxyg\u00e9nase (15-LO), une enzyme qui est un r\u00e9gulateur cl\u00e9 des voies \u00e9nerg\u00e9tiques et du stress oxydatif qui sont perturb\u00e9s dans l&#8217;ataxie de Friedreich. Dans les suites de la r\u00e9alisation d\u2019un \u00e9tude de phase II\/III ( \u00e9tude MOVE-FA) PTC Therapeutics a demand\u00e9 [&hellip;]"}